Consumer skepticism

The supplement aisle audit

The aisle loves hair loss. The literature mostly doesn't love the aisle back.

By the Editorial Team · Citations below · Medical review: pending — treat as education, not advice

Key points

Dietary supplements are not FDA-reviewed for efficacy before sale — that's the legal category, not a scandal, but it shifts the burden of proof onto you.
Saw palmetto has small positive studies; the effect sizes and study quality sit far below the approved-drug evidence base.
Biotin helps documented deficiency, which is rare; evidence for regrowth in healthy men is essentially absent.
"Proprietary blend" labels make a product un-evaluable by design.

The rule we apply

If a claim would need a drug-style trial to prove, and no such trial exists, treat the claim as marketing. That single rule disposes of most of the aisle.

Saw palmetto

The theory is plausible — saw palmetto extracts weakly inhibit 5-alpha-reductase, the same pathway finasteride targets pharmaceutically. The data: small trials, including a 2012 two-year comparative study (about 100 men) in which roughly 38% of saw palmetto users saw some improvement versus 68% with finasteride 1 mg, with saw palmetto's effect concentrated at the vertex. Read generously, a weak signal; read rigorously, underpowered studies of non-standardized extracts. It is not "natural finasteride."

Biotin

Biotin earns its reputation from genuine deficiency states — which are rare in people eating a normal diet. A 2017 review found that essentially all reported hair benefits occurred in patients with a documented deficiency or an underlying pathology; evidence for supplementation in healthy individuals was lacking. Bonus problem: high-dose biotin can interfere with common lab tests, including thyroid and cardiac assays — worth telling your doctor about before bloodwork.

Proprietary blends and "clinically proven"

A proprietary blend lists ingredients without amounts, which makes dose-response comparison with any published study impossible — by design. And "clinically proven" on a label often traces to a small, company-funded study of the product itself, sometimes unpublished. Questions that cut through: Which trial? How many subjects? Versus what control? Published where?

What this means practically

Nutritional status matters — crash diets, iron deficiency, and thyroid conditions genuinely cause hair problems and deserve a clinician's attention, not a shelf solution. But for androgen-driven pattern loss, no supplement has evidence in the same class as the approved options. Money spent on the aisle is usually buying hope at a markup.

This article is education, not medical advice, and doesn't create a clinician-patient relationship. We are independent: no pharmaceutical or supplement funding, nothing to sell you.

Citations

Rossi A, et al. Comparative effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. Int J Immunopathol Pharmacol. 2012;25(4):1167-1173.
Patel DP, Swink SM, Castelo-Soccio L. A review of the use of biotin for hair loss. Skin Appendage Disord. 2017;3(3):166-169.
U.S. Food and Drug Administration. The FDA warns that biotin may interfere with lab tests: FDA Safety Communication (2017, updated 2019).